Skip to main content
Questions About LUTATHERA

When your doctor decides that treatment with LUTATHERA is right for you, it’s not uncommon to have questions.

What is LUTATHERA and how might it help me?
LUTATHERA is the first and only approved radioligand therapy (also known as RLT) for GEP-NETs, a medicine from a class of drugs called peptide receptor radionuclide therapy (also known as PRRT).

LUTATHERA is believed to work differently from most cancer medicines, with a 2-part approach that specifically targets and enters the cells that have somatostatin receptors, releasing energy in the form of radiation that damages them and nearby cells.

Who can LUTATHERA help?
LUTATHERA may help people with GEP-NETs.

LUTATHERA may help people who have already tried long-acting octreotide by itself. LUTATHERA may also help people who were newly diagnosed with GEP-NETs.

What is progression-free survival?
Progression-free survival, also known as PFS, is the length of time during which people have not had their disease worsen or died since starting treatment.

Measuring progression-free survival is 1 way to see how well LUTATHERA is working for you.

If I do move forward with LUTATHERA treatment, what are some things I should inform my health care professional about?
It’s important to tell your health care professional everything about your disease and health status. Health information you may want to discuss includes:

  • Any medical conditions you may have

  • Symptoms you may have

  • Any changes in your daily habits

  • If you have trouble controlling when you urinate or have a bowel movement

  • All of the medicines you are taking, including over-the-counter medicines

  • If you are trying to get pregnant, if you are already pregnant, or if you are breastfeeding

Make sure to let your health care professional know if you are taking either a type of medicine called a somatostatin analog, also called an SSA, and/or glucocorticoids. If you are taking either, you might have to stop or change your treatment while receiving LUTATHERA.

  • If you are a female who is able to get pregnant, use effective contraception during treatment with LUTATHERA and for 7 months after the last dose

  • If you are a male with a female partner who is able to get pregnant, use effective contraception during treatment with LUTATHERA and for 4 months after the last dose

  • Women should not breastfeed during treatment with LUTATHERA and for 2.5 months after the last dose

What financial support is available?
Novartis Patient Support provides dedicated, ongoing help and resources starting when you sign up.

For information about Novartis Patient Support, call 1-844-638-7222.

Where can I find a treatment center to receive LUTATHERA?
Speak with your health care professional to see if starting LUTATHERA is right for you. Find a LUTATHERA treatment site in the United States. Learn more

Important Safety Information

What are some important things to know about the safety of LUTATHERA?

LUTATHERA is associated with some serious safety considerations and, in some cases, these may require your health care provider to adjust or stop...

Approved Use

What is LUTATHERA?

LUTATHERA® (lutetium Lu 177 dotatate) is a prescription medicine used to treat adults with a type of cancer known as gastroenteropancreatic neuroendocrine tumors (GEP-NETs) that are positive...

Click or scroll to see IMPORTANT SAFETY INFORMATION AND APPROVED USE